Project Grant R01HL175990
Award Date
6/1/25
Completion Date
3/31/29
Dollars Obligated
$759K
Federal Agency
National Heart Lung and Blood Institute
Awardee
Yale Univ (FL6GV84CKN57)
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Connecticut, USA
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $769,789 to The Leland Stanford Junior University to develop a catheter-injectable, engineered biomaterial for sustained delivery of the protein therapy neuregulin-1 (NRG1) to the myocardium for the treatment of myocardial infarction (MI). The key objectives are to: 1) Evaluate a novel crosslinked hydrogel formulation (HA-LINC) that...
This federal Project Grant award, totaling $385,381.00, was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) program. The objective is to develop and evaluate injectable, dynamic silk-based hydrogels containing fetal cardiac extracellular matrix (CECM) to promote mechanical stabilization and favorable remodeling of the infarcted ventricular wall following myocardial infarction. The research will assess the impact of...
This $647,359 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports the engineering of biomaterials with controlled biomolecule delivery for cardiovascular applications. The key products and services to be delivered include: Efficient and sustainable delivery of microRNA-145 from a novel biomaterial (PVA-CDI immobilized aminated fucoidan, or PCAF) to smooth muscle cells to induce a contractile...
The U.S. National Heart, Lung, and Blood Institute (NHLBI) awarded a $498,991.40 Project Grant to the University of Arkansas under the Cardiovascular Diseases Research (CFDA 93.837) federal grant program. The funding supports the development of microphysiological systems to study hypoxic cardiac injury resulting from acute myocardial infarction and ischemia-reperfusion injury. The research aims to engineer microfluidic devices to precisely control oxygen levels and investigate how oxygen...
This $686,458 Project Grant was awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The grant supports a collaborative research effort between multiple institutions, led by Yale University, to develop a quantitative, predictive model of vascular remodeling in health and disease. The key products and services to be delivered through this grant include: Characterizing the roles of vascular endothelial...
This $720,676 Project Grant award was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Pittsburgh. The research aims to develop a novel therapeutic strategy using ultrasound-targeted microbubble cavitation (UTMC) to deliver nitro-fatty acid microbubbles (NFABs) to treat microvascular obstruction and post-myocardial infarction fibrosis. The project will evaluate the efficacy of UTMC with NFABs...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $785,198 to Albert Einstein College of Medicine for research on the role of chaperone-mediated autophagy (CMA) in cardiac fibrosis and repair following myocardial infarction. The research aims to study how CMA regulates the phenotypic transitions and functions of fibroblasts and myofibroblasts in the infarcted heart, with the goal...
The U.S. National Heart, Lung, and Blood Institute (NHLBI) awarded a $989,908 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Nevada, Las Vegas (UNLV). This 4-year grant supports research to evaluate the efficacy of Wnt11-treated mesenchymal stem cells (MSCs) for improving cardiac repair following myocardial infarction. The key objectives are to: 1) examine whether Wnt11 treatment can enhance MSC resistance to apoptosis and improve cell...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $777,258 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program to Beth Israel Deaconess Medical Center, Inc. (Bidmc) in Boston, Massachusetts. The grant, with a period of performance from February 25, 2025 to January 31, 2030, aims to improve the understanding of heart failure in hypertrophic cardiomyopathy (HCM) through novel cardiac magnetic resonance imaging (CMR) techniques. The research will investigate...
This $496,367 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) aims to develop novel approaches for in situ cardiac reprogramming. The key objectives are to: Investigate the mechanism by which a repressor complex inhibits cardiomyocyte gene expression, including testing if knockdown of individual repressors can recapitulate the effects of combined knockdown. Determine if targeting the repressor complex...